Browsing Category
Pharma Industry News
4744 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
BioCity’s SC0062 secures second breakthrough therapy designation in China for diabetic kidney disease
BioCity Biopharma’s ETA-selective SC0062 earns second Breakthrough Therapy Designation in China for diabetic kidney disease, reinforcing its CKD potential.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
Sun Pharmaceutical faces regulatory pause as EMA application for melanoma drug withdrawn
Sun Pharmaceutical’s EU partner Philogen has withdrawn its EMA application for Nidlegy, delaying regulatory progress in melanoma care. Read what’s next.
Percheron Therapeutics (ASX: PER) licenses HMBD-002 cancer drug from Hummingbird in oncology pivot
Percheron Therapeutics acquires global rights to phase II-ready cancer drug HMBD-002 from Hummingbird Bioscience. Learn what this means for investors.
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
Archeus Technologies receives FDA clearance for ART-101 to begin prostate cancer therapy trials in 2025
Archeus Technologies wins FDA IND clearance for ART-101, an alpha-emitting radiopharmaceutical therapy targeting PSMA in advanced prostate cancer.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
JR-446 developed by JCR Pharmaceuticals secures orphan drug designation from the European Commission for MPS IIIB
The European Commission has granted orphan drug status to JR-446 for MPS IIIB, supporting JCR Pharmaceuticals’ global rare disease expansion.
Breckenridge Pharmaceutical receives FDA approval for dehydrated alcohol injection, strengthening its institutional strategy
Breckenridge secures FDA approval for its generic dehydrated alcohol injection, boosting institutional reach for cardiac therapy. Read more on market strategy.